Header
For Healthcare Professionals
Metalyse Logo
Metalyse Banner
METALYSE® 25 MG IS NOW AVAILABLE FOR THE THROMBOLYTIC TREATMENT OF ACUTE ISCHAEMIC STROKE WITHIN 4.5 HOURS FROM LAST KNOWN WELL AND AFTER EXCLUSION OF INTRACRANIAL HAEMORRHAGE1

Because Every
Minute Matters

Stroke affects more than 12 million people each year. It is the second leading cause of death worldwide. Unfortunately, this number is expected to rise because of an ageing global population.2
Acute ischaemic stroke (AIS) occurs when a vessel supplying blood to the brain is obstructed, depriving brain tissue of oxygen and nutrients. If blood flow is not restored fast enough, damage to brain cells in a particular area can lead to permanent disability and even death3-5. That’s why when it comes to stroke, every minute matters.

Metalyse® 25 mg (tenecteplase) has a similar safety profile to Actilyse® (alteplase)§3

Time is Brain


Time is Brain

Footnotes

  • AIS: acute ischaemic stroke

References

  1. Metalyse® European Summary of Product Characteristics.

  2. World Stroke Organization, https://www.world-stroke.org/world-stroke-day-campaign/about-stroke/impact-of-stroke.

  3. American Heart Association, www.stroke.org/-/media/Stroke-Files/Lets-Talk-About-Stroke/About-Stroke/Lets-Talk-about-Stroke-TIA-Warning-Signs.pdf.

  4. Donkor ES. Stroke Res Treat. 2018;3238165. 

  5. Sacco RL, et al. Stroke 2013;44:2064-2089. 

  6. Saver JL. Stroke 2006;37:263-266. 

  7. Saver JL, et al. Stroke 2010;41(7):1431-1439. 

  8. Advani R, et al. Scand J. Trauma Resusc Emerg Med. 2017;25(1): 54. 

  9. Almekhlafi MA, et al. JAMA Neurol. 2021;78(6):709-717.

  10. He AH, et al. Int J. Stroke 2015;10(7):1062-1067.